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1. Introduction 
The diagnosis of muscular dystrophies (MDs) has advanced considerably since these 
disorders were first described in the 1800s, due to characterisation of phenotypes and 
advances in biochemical and molecular analyses. Over the last ten years in particular, there 
has been a rapid expansion in the list of genes that are known to cause MD. Providing a 
specific genetic diagnosis to a patient is important for many reasons. It resolves many 
uncertainties for families, enables accurate genetic counselling and options for prevention and 
prenatal diagnosis, and provides doctors and families with information about prognosis, 
which allows medical care to be individualised. In some cases, a genetic diagnosis prompts the 
clinician to begin surveillance and/or interventions that may be life-saving, such as aggressive 
cardiac surveillance in disorders associated with cardiac arrhythmias or cardiomyopathy. In 
addition, knowledge of the primary genetic cause will be an essential prerequisite to prescribe 
specific gene-based or biochemical therapies when they are developed in the future. Making a 
genetic diagnosis should now be the universal goal for all patients with MD. 
Diagnosis of the three most common forms of MD, Duchenne muscular dystrophy (DMD), 
myotonic dystrophy and Facioscapulohumeral muscular dystrophy (FSHD) MD, is now 
straightforward in most patients, as clinical features guide the appropriate genetic tests to be 
requested. However, establishing the specific diagnosis in many patients with other forms of 
MD remains difficult. The main reasons are the large number of potential genetic causes in 
several subgroups of MD, a lack of specific features to guide diagnosis and the wide range 
of phenotypes that are possible with many genetic forms. These combine to make it a 
challenge for the clinician to predict the correct genetic cause from the patient’s clinical 
presentation and history, or from standard clinical tests alone. Laboratory investigations, 
including muscle histopathology and protein analysis (immunohistochemistry and Western 
blotting), are useful to guide genetic testing in many situations. However, even in well-
resourced diagnostic services, the genetic cause remains unknown in a large proportion of 
MD patients. It is likely that many of these patients have as yet undiscovered genetic forms 
of MD.  
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This chapter summarises the most important clinical and laboratory information to consider 
when diagnosing MDs, and the approach to diagnosing the different forms. This includes an 
appreciation of clinical presentations, the use of specialised muscle imaging, muscle 
histopathology, laboratory protein analysis and specific genetic tests. We also discuss the 
challenges when diagnosing many rare forms of MD, and how new technologies may aid 
this process. 
2. The different forms of muscular dystrophy 
The MDs are a genetically and phenotypically diverse group of disorders. In children, the 
most common form of MD is Duchenne MD (DMD), caused by mutations in the DMD gene 
that encodes dystrophin, with an estimated prevalence of 1 in 3000 males (Jones and North 
1997). Most affected boys lose ambulation around 10 years of age and die from respiratory 
or cardiac complications in the third or fourth decades of life. Becker MD (BMD) is a less 
severe condition associated with a later age of onset and slower disease progression that is 
also caused by mutations in the dystrophin protein.  
In adults, the most common forms of MD are myotonic dystrophy type 1 (DM1) and 
facioscapulohumeral MD (FSHD). The average estimated prevalence of DM1 is ~1 in 10,000 
(Norwood, Harling et al. 2009; Turner and Hilton-Jones 2010) and for FSHD it is 1 in 20,000 
(Norwood, Harling et al. 2009; Statland and Tawil 2011). DM1 is a multi-system disorder 
caused by a trinucleotide repeat expansion (CTG) in the DMPK gene on chromosome 19 and 
there is a wide range of severity that partially correlates with the size of the repeat 
expansion (McNally and Pytel 2007; Turner and Hilton-Jones 2010). The classical form of 
DM1 is characterised by progressive muscle weakness that begins in the muscles of the face, 
ankle, hands and neck and myotonia, a delayed relaxation of muscles after contraction. 
Patients also have an increased risk of cardiac conduction defects, cataracts, type 2 diabetes, 
daytime somnolence and balding (males especially). Congenital onset DM1 is strongly 
associated with respiratory difficulties at birth and intellectual disabililty (Turner and 
Hilton-Jones 2010). A second form of myotonic dystrophy (DM2) is due to mutations in the 
ZNF9 gene, does not have a congenital onset form, and is probably less common. FSHD is 
characterised by weakness of the facial, scapular, ankle and upper arm muscles and is 
caused by deletions of large D4Z4 DNA repeats in the sub-telomeric region of chromosome 
4q (McNally and Pytel 2007; Pandya, King et al. 2008). 
 
Disease  Gene Chromosome Protein Year Identified 
FSHD DUX4 4q35 Double homeobox 4 1990 1 
Myotonic Dystrophy 
(DM1) 
DMPK 19q13 Expansion of non-coding 
triplet (CTG) repeat 
1992 2,3 
Myotonic Dystrophy 
(DM2) 
ZNF9 3q21 Expansion of non-coding 
quadruplet (CCTG) repeat 
2001 4,5 
Oculopharyngeal MD PABPN1 14q11.2-q13 Poly(A) binding protein, 
nuclear 1 
1998 6-8 
MD with 
Lipodystrophy 
PTRF 17q21-23 Cavin-1 2009 9 
DMD/BMD DMD Xp21.2 Dystrophin 1986/87 10-14 
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Disease  Gene Chromosome Protein Year Identified 
EDMD EMD 
FHL1 
 
LMNA 
SYNE1 
SYNE2 
Xq28 
Xq27.2 
 
1q21.2 
6q25 
14q23 
Emerin 
Four and a half LIM domain 
1 
Lamin A/C 
Nesprin-1 
Nesprin-2 
1994 15 
2009 16 
 
1999 17 
2007 18 
2007 18 
LGMD1A MYOT 5q31 Myotilin 2000 19 
LGMD1B LMNA 1q22  Lamin A/C 2000 20 
LGMD1C CAV3 3p25 Caveolin-3 1998 21,22 
LGMD1D * 7q36.3  23 
LGMD1E * 6q23  24 
LGMD1F * 7q32  25 
LGMD1G * 4q21  26 
LGMD2A CAPN3 15q15.1 Calpain-3 1995 27,28 
LGMD2B DYSF 2p13 Dysferlin 1998 29,30 
LGMD2C SGCG 13q12 -sarcoglycan 1995 31 
LGMD2D SGCA 17q12-21.33 -sarcoglycan 1994 32 
LGMD2E SGCB 4q12 -sarcoglycan 1996 33 
LGMD2F SGCD 5q33 -sarcoglycan 1996 34 
LGMD2G TCAP 17q12 Telethonin 2000 35 
LGMD2H TRIM32 9q31-34 Tripartite motif-containing 
32 
2002 36,37 
LGMD2I FKRP 19q13.3 Fukutin related protein 2001 38,39 
LGMD2J TTN 2q31 Titin 2002 40 
LGMD2K POMT1 9q34 Protein O-mannosyl-
transferase 1 
2005 41 
LGMD2L ANO5 11p14.3 Anoctamin 5 2010 42 
LGMD2M FKTN 9q31-33 Fukutin 2006 43,44 
LGMD2N POMT2 14q24 Protein O-mannosyl-
transferase 2 
2007 45 
LGMD2O POMGnT1 1p34 Protein O-linked mannose 
beta 1,2-N-
acetylglucosaminyl 
transferase 1 
2007 46 
MDC1A LAMA2 6q2 Laminin 2 chain of merosin 1995 47-49 
MDC1B * 1q42  50 
MDC1C FKRP 19q13 Fukutin related protein 2001 51 
MDC1D LARGE 22q12 Like-glycosyltransferase 2003 52 
FCMD FCMD 9q31-33 Fukutin 1998 53,54 
WWS FCMD 
POMT1 
 
POMT2 
 
FKRP 
POMGnT1 
9q31-33 
9q34 
 
14q24.3 
 
19q13 
1p3 
Fukutin 
Protein O-mannosyl-
transferase 1 
Protein O-mannosyl-
transferase 2 
Fukutin related protein 
Protein O-linked mannose 
beta 1,2-N-
acetylglucosaminyl 
transferase 1 
2003 55 
2002 56 
 
 
2005 57 
2005 58 
2003 59 
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Disease  Gene Chromosome Protein Year Identified 
MEB POMGnT1 
 
 
 
FKRP 
POMT2 
1p3 
 
 
 
19q13 
14q24.3 
Protein O-linked mannose 
beta 1,2-N-
acetylglucosaminyl 
transferase 1 
Fukutin related protein 
Protein O-mannosyl-
transferase 2 
2001 60 
 
 
 
2005 58 
2006 61 
Rigid Spine Syndrome SEPN1 1p36 Selenoprotein N1 2001 62,63 
UCMD COL6A1 
COL6A2 
COL6A3 
21q22.3 
21q22.3 
2q37 
Collagen VI, subunit 1 
Collagen VI, subunit 2 
Collagen VI, subunit 3 
2003 64,65 
2001 66,67 
2002 68 
Bethlem myopathy COL6A1 
COL6A2 
COL6A3 
21q22.3 
21q22.3 
2q37 
Collagen VI, subunit 1 
Collagen VI, subunit 2 
Collagen VI, subunit 3 
1996 69 
1996 69 
1998 70,71 
CMD integrin defect ITGA7 12q13 Integrin 7 1998 72 
CMD dynamin 2 defect DNM2 19p13.2 Dynamin 2 2008 73 
CMD joint hyperlaxity * 3p23-21  74 
Adapted from the NMD Gene Table 2011 (Kaplan 2010). * = no gene discovered yet. Abbreviations: 
FSHD: Facio-scapulo-humeral MD, MD: muscular dystrophy, DMD: Duchenne MD, BMD: Becker MD, 
EDMD: Emery-Dreifuss MD, LGMD: limb-girdle MD, MDC: MD congenital, FCMD: Fukuyama 
congenital MD, WWS: Walker-Warburg Syndrome, MEB: Muscle-eye-brain disease, UCMD: Ullrich 
congenital MD and CMD: congenital MD. References: 1(Wijmenga, Frants et al. 1990), 2(Brook, 
McCurrach et al. 1992), 3(Renwick, Bundey et al. 1971), 4(Liquori, Ricker et al. 2001), 5(Ranum, 
Rasmussen et al. 1998), 6(Brais, Bouchard et al. 1998), 7(Brais, Xie et al. 1995), 8(Robinson, Hammans et 
al. 2005), 9(Hayashi, Matsuda et al. 2009), 10(Burghes, Logan et al. 1987), 11(Hoffman, Brown et al. 
1987), 12(Koenig, Hoffman et al. 1987), 13(Koenig, Monaco et al. 1988), 14(Monaco, Neve et al. 1986), 
15(Bione, Maestrini et al. 1994), 16(Gueneau, Bertrand et al. 2009), 17(Bonne, Di Barletta et al. 1999), 
18(Zhang, Bethmann et al. 2007), 19(Hauser, Horrigan et al. 2000), 20(Muchir, Bonne et al. 2000), 
21(McNally, de Sa Moreira et al. 1998), 22(Minetti, Sotgia et al. 1998), 23(Speer, Vance et al. 1999), 
24(Messina, Speer et al. 1997), 25(Palenzuela, Andreu et al. 2003), 26(Starling, Kok et al. 2004), 
27(Richard, Brenguier et al. 1997), 28(Richard, Broux et al. 1995), 29(Bashir, Britton et al. 1998), 30(Liu, 
Aoki et al. 1998), 31(Noguchi, McNally et al. 1995), 32(Roberds, Leturcq et al. 1994), 33(Bonnemann, 
Passos-Bueno et al. 1996), 34(Nigro, de Sa Moreira et al. 1996), 35(Moreira, Wiltshire et al. 2000), 
36(Frosk, Weiler et al. 2002), 37(Weiler, Greenberg et al. 1998), 38(Brockington, Blake et al. 2001), 
39(Driss, Amouri et al. 2000), 40(Hackman, Vihola et al. 2002), 41(Balci, Uyanik et al. 2005), 42(Bolduc, 
Marlow et al. 2010), 43(Godfrey, Escolar et al. 2006), 44(Murakami, Hayashi et al. 2006), 45(Biancheri, 
Falace et al. 2007), 46(Godfrey, Clement et al. 2007), 47(Helbling-Leclerc, Zhang et al. 1995), 48(Hillaire, 
Leclerc et al. 1994), 49(Tome, Evangelista et al. 1994), 50(Brockington, Sewry et al. 2000), 51(Brockington, 
Blake et al. 2001), 52(Longman, Brockington et al. 2003), 53(Kobayashi, Nakahori et al. 1998), 54(Toda, 
Segawa et al. 1993), 55(de Bernabe, van Bokhoven et al. 2003), 56(Beltran-Valero de Bernabe, Currier et 
al. 2002), 57(van Reeuwijk, Janssen et al. 2005), 58(Beltran-Valero de Bernabe, Voit et al. 2004), 
59(Taniguchi, Kobayashi et al. 2003), 60(Yoshida, Kobayashi et al. 2001), 61(Mercuri, D'Amico et al. 
2006), 62(Moghadaszadeh, Desguerre et al. 1998), 63(Moghadaszadeh, Petit et al. 2001), 64(Giusti, 
Lucarini et al. 2005), 65(Pan, Zhang et al. 2003), 66(Camacho Vanegas, Bertini et al. 2001), 67(Higuchi, 
Shiraishi et al. 2001), 68(Demir, Sabatelli et al. 2002), 69(Jobsis, Keizers et al. 1996), 70(Pan, Zhang et al. 
1998), 71(Speer, Tandan et al. 1996), 72(Hayashi, Chou et al. 1998), 73(Susman, Quijano-Roy et al. 2010), 
74(Tetreault, Duquette et al. 2006) and 75(Kaplan 2010). 
Table 1. Table of muscular dystrophy genes and proteins.  
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The other major forms of MD are grouped by age of onset or clinical phenotype (see Table 
1). Each specific genetic form of MD has a characteristic pattern of disease onset, severity, 
clinical course and involvement of particular muscle groups, although there is marked 
overlap between phenotypes (see Table 2). The congenital MDs (CMD) are characterised by 
onset of muscle weakness within the first year of life (often at birth) and usually have a 
slowly progressive disease course. In the limb girdle MDs (LGMD), patients can present 
during childhood or adulthood with weakness that is most prominent in proximal limb or 
shoulder and/or pelvic girdle muscles. They are subdivided based on mode of inheritance 
into LGMD type 1 (autosomal dominant) and LGMD type 2 (autosomal recessive); DMD 
and BMD can be considered as X-linked forms of LGMD. Emery Dreifuss MD (EDMD) is a 
clinical syndrome with several possible genetic causes characterised by prominent weakness 
in the upper arm and ankle dorsiflexor muscles, early contractures of the elbows, ankles and 
neck and cardiac involvement. Other forms of MD with notable phenotypes are 
oculopharyngeal MD, where mainly the muscles of the eye and throat are affected, and the 
distal myopathies which mainly affect the muscles of the hands and feet.  
In addition to the different forms of MD listed so far, a wide range of muscle conditions 
have clinical and histological features that overlap with the MDs and these should be kept in 
mind whenever a diagnosis of a MD is considered. The most important differential 
diagnoses are the myofibrillar myopathies (characterised by desmin-positive inclusions in 
muscle fibres, prominent distal limb muscle involvement, cardiomyopathy and peripheral 
neuropathy) and some severe forms of congenital myopathy (especially those due to RYR1 
and DNM2 mutations). 
3. Overview of the approach to diagnosis 
A diagnosis of MD usually begins with a patient presenting with muscle weakness, muscle 
pain, reduced stamina; or in children, delayed motor development. Occasionally a raised 
serum creatine kinase (CK) level is the first sign of a MD and an incidental finding during 
investigation of other symptoms. A detailed clinical history and examination can provide 
important clues about the diagnosis and the most appropriate path of investigation. Muscle 
imaging is a non-invasive option that may be helpful in particular situations. A muscle 
biopsy is still required for the diagnosis of many types of MD. In most children and some 
adults a skin biopsy is taken for fibroblast cell culture at this time. Standard muscle 
histopathology provides information about muscle architecture and frozen portions of the 
muscle biopsy can be used for a range of protein analyses. Information from all of these 
sources is used to direct genetic testing, which usually provides the definitive diagnosis. 
This process is outlined in Figure 1. 
3.1 Clinical information 
Clinical information remains of paramount importance in the diagnostic process, even with 
recent advances in genetics (Bushby, Norwood et al. 2007; Norwood, de Visser et al. 2007; 
Guglieri and Bushby 2008). Each MD has a characteristic clinical pattern in terms of age of 
onset, rate of progression, severity and range of muscles involved. In some forms of MD, the 
pattern of clinical features is sufficiently distinct for a relatively accurate provisional  
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Abbreviations: EMG: Electromyography, NCS: nerve conduction studies, MRI: magnetic resonance 
imaging. 
Fig. 1. Overview of MD diagnostic process. 
diagnosis to be made on the basis of clinical history, examination and some basic clinical 
tests. This is the case for the three most common forms of MD - myotonic dystrophy, FSHD 
and DMD. It is recommended that clinician spends time familiarising themselves with these 
three disorders in particular, as they are the most common conditions encountered. Genetic 
testing is widely available for these conditions and many patients no longer require a 
muscle biopsy, so long as the clinician can make an accurate provisional diagnosis from 
clinical features.  
Age of disease onset is a key feature that is used to classify major subgroups of MD. The 
congenital muscular dystrohies (CMDs) present in the first two years of life, most often at 
birth. The limb girdle MDs (LGMDs) begin after age 2 years. Onset can vary  
between the first decade of life to old age depending on the specific form of LGMD and its 
severity.  
The pattern of weakness may also provide clues to the MD subtype. For example while 
LGMDs are characterised by proximal weakness, some subtypes may also have significant 
involvement of scapular stabilisers or distal limb muscles (see Table 2). Other important 
variables include the presence or absence of brain, cardiac or respiratory  
muscle involvement, calf muscle hypertrophy, contractures and skin abnormalities (see 
Table 2). 
The level of creatine kinase (CK) in blood, which is thought to be a marker of ongoing 
muscle necrosis or damage, can also help to differentiate between forms of MD. While some 
fluctuation in CK levels from day to day occurs and there is a tendency for CK levels to drop 
with disease progression, categorising CK results into broad ranges such as normal, mildly 
raised, moderately raised and markedly elevated is useful. 
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FSHD DUX4 Common 10-50 ↑-↑↑       CE, FHx, 
GT 
1,2 
Myotonic 
Dystrophy 
(DM1) 
DMPK Common 0-80 ↑-↑↑       CE, FHx, 
EMG, GT 
3 
Myotonic 
Dystrophy 
(DM2) 
ZNF9 Probably 
uncommon 
10-60 ↑-↑↑       CE, FHx, 
EMG, GT 
3 
DMD-BMD DMD Common DMD: 2-6  
BMD:>5 
↑↑-↑↑↑       CE, FHx, 
IHC, WB, 
GT, SEQ 
4,5 
EDMD EMD 
FHL1 
LMNA 
Uncommon 
Rare 
Uncommon 
>3 
4-48 
>3 
↑-↑↑ 
N-↑↑ 
N-↑↑ 
  
 
 
   
 
 
 
 
 
IHC, WB, 
SEQ 
SEQ 
SEQ 
6,7 
8 
LGMD1A MYOT Rare >25 ↑-↑↑       SEQ 9 
LGMD1B LMNA Uncommon >3 ↑-↑↑         SEQ 10 
LGMD1C CAV3 Uncommon >4 ↑↑-↑↑↑       IHC, WB, 
SEQ 
11 
LGMD2A CAPN3 Common 2-40 ↑-↑↑↑       ± WB, SEQ 12,13 
LGMD2B DYSF Moderately 
common^ 
12-25 ↑↑↑       IHC, WB, 
SEQ 
14-
16 
LGMD2C SGCG Rare >3   ↑↑-↑↑↑       IHC, WB, 
SEQ 
17-
21 
LGMD2D SGCA Rare >3  ↑↑-↑↑↑       IHC, WB, 
SEQ 
17-
21 
LGMD2E SGCB Rare >3  ↑↑-↑↑↑       IHC, WB, 
SEQ 
17-
21 
LGMD2F SGCD Rare >3  ↑↑-↑↑↑       IHC, WB, 
SEQ 
17-
21 
LGMD2G TCAP Rare 9-20  ↑-↑↑↑  ?      IHC, SEQ 22,23 
LGMD2H TRIM32 Rare‡ 8-30 ↑↑-↑↑↑       SEQ 24 
LGMD2I FKRP Common 2-40 ↑↑-↑↑↑       IHC+, 
WB+, SEQ 
25 
LGMD2J TTN Rare 8-30 N-↑       MRI, 
(SEQ) 
26 
LGMD2L ANO5 Common >17 ↑↑↑        SEQ 27,28 
MDC1A LAMA2 Common 0 ↑↑-↑↑↑        IHC, WB, 
SEQ 
29-
32 
MDC1C FKRP Rare 0 ↑↑↑        IHC+, 
WB+, SEQ 
33 
FCMD FKTN Common† 0 ↑↑-↑↑↑        IHC+, 34 
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WB+, SEQ 
Rigid Spine 
Syndrome 
SEPN1 Uncommon 0-2 N-↑       SEQ 35 
UCMD COL6A1-3 Common 0 N-↑↑        IHC, FIBS, 
SEQ 
36-
38 
Bethlem 
myopathy 
COL6A1-3 Common 2-20 N-↑↑       FIBS, SEQ 36,38 
This table does not include the rarest forms of muscular dystrophy. Brain involvement can be seen in 
congenital myotonic dystrophy (DM1), DMD, the α-dystroglycanopathies and MDC1A. * = Prevalence 
varies for some disorders in different populations. Distal = prominent distal limb muscle involvement. CK = 
creatine kinase. Spine = prominent scoliosis or spinal rigidity. N = CK within normal range, ↑ = CK level 1 to 
4 times upper limit of normal, ↑↑ = CK 4 to 15 times upper limit of normal, ↑↑↑ = CK > 15 times upper limit 
of normal. = commonly associated, = key feature for diagnosis and/or management. ^ = in Indian 
subcontinent especially, ‡ = mainly reported in Manitoba Hutterites, † = mainly reported in Japanese. CE = 
important clinical examination findings, FHx = clues from family history, GT = specific genetic test (other 
tthan full gene sequencing), EMG = Electromyography, IHC = immunohistochemistry, WB = Western blot, 
SEQ = direct gene sequencing, MRI = magnetic resonance imaging, FIBS = fibroblast culture, + = protein 
studies assess levels of glycolsylated α-dystroglycan. References: 1(Statland and Tawil 2011), 2(Sorrel-
Dejerine and Fardeau 1982), 3(Turner and Hilton-Jones 2010), 4(Bushby, Finkel et al. 2010), 5(Jones and 
North 1997), 6(Bonne, Mercuri et al. 2000), 7(Emery 1989), 8(Gueneau, Bertrand et al. 2009), 9(Hauser, 
Horrigan et al. 2000), 10(van der Kooi, van Meegen et al. 1997), 11(Minetti, Sotgia et al. 1998), 12(Fardeau, 
Hillaire et al. 1996), 13(Piluso, Politano et al. 2005), 14(Bushby, Bashir et al. 1996), 15(Guglieri, Magri et al. 
2008), 16(Zatz, de Paula et al. 2003), 17(Azibi, Bachner et al. 1993), 18(Bonnemann, Passos-Bueno et al. 1996), 
19(Jones, Kim et al. 1998), 20(Lim, Duclos et al. 1995), 21(Passos-Bueno, Moreira et al. 1996), 22(Moreira, 
Vainzof et al. 1997), 23(Moreira, Wiltshire et al. 2000), 24(Borg, Stucka et al. 2009), 25(Brockington, Yuva et al. 
2001), 26(Udd, Partanen et al. 1993), 27(Bolduc, Marlow et al. 2010), 28(Hicks, Sarkozy et al. 2011), 
29(Allamand and Guicheney 2002), 30(Jones, Morgan et al. 2001), 31(North, Specht et al. 1996), 32(Tome 
1999), 33(Brockington, Blake et al. 2001), 34(Toda and Kobayashi 1999), 35(Moghadaszadeh, Petit et al. 2001), 
36(Bertini and Pepe 2002), 37(Nadeau, Kinali et al. 2009),and 38(Peat, Smith et al. 2008). 
Table 2. Discriminating clinical features in genetically characterised muscular dystrophies. 
3.2 Muscle pathology 
The MDs are characterised by the presence of ‘dystrophic’ changes on muscle biopsy and 
one should be cautious about making a diagnosis of a MD if these are not present. The 
specific pathological features that in combination signify a dystrophy include variation in 
fibre size, increased internal nuclei, increased connective and adipose tissue, (Norwood, de 
Visser et al. 2007) and the presence of regenerating and degenerating fibres (see Figure 2). In 
addition, fibre splitting and inflammatory cell infiltrates are sometimes seen in MDs but are 
less specific for these disorders. These histological features likely arise from recurrent 
episodes of muscle fibres necrosis and regeneration that occur because fibres are more prone 
to damage than normal during muscle contraction (Jones and North 1997; Voit 2001). The 
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relative prominence of different dystrophic features varies depending on the specific type of 
dystrophy, the age of the patient and the muscle biopsied (since the degree of involvement 
varies among different muscle groups in different dystrophies). 
It is rarely possible to define the genetic cause of a MD from biopsy features alone but the 
pattern of dystrophic features can provide clues about the diagnosis. For example, dystrophic 
changes are often mild in the caveolinopathies (Minetti, Sotgia et al. 1998; Waddell, Lemckert 
et al. 2011), and the laminopathies (Quijano-Roy, Mbieleu et al. 2008; Rankin, Auer-Grumbach 
et al. 2008) compared to the dystrophinopathies and sarcoglycanopathies (Bonnemann, Passos-
Bueno et al. 1996; Eymard, Romero et al. 1997). LGMD2B (dysferlin) (Norwood, de Visser et al. 
2007) and LGMD2L (anoctamin-5) (Hicks, Sarkozy et al. 2011) often have an infiltration of 
inflammatory cells as an additional feature, and patients can be initially misdiagnosed with 
polymyositis (Norwood, de Visser et al. 2007). Young patients with Ullrich congenital 
muscular dystrophy (UCMD) (collagen VI) may only show non-specific myopathic changes or 
congenital fibre type disproportion (CFTD) (Peat, Smith et al. 2008; Schessl, Goemans et al. 
2008). Mutations in SEPN1 can cause various changes on muscle pathology including those 
resembling CMD, multiminicore disease or CFTD (Ferreiro, Quijano-Roy et al. 2002; Clarke, 
Kidson et al. 2006). The presence of other pathological abnormalities can be a clue to specific 
disorders, such as rimmed vacuoles which are associated with LGMD2G (telethonin) (Moreira, 
Vainzof et al. 1997) and LGMD2J (Udd, Partanen et al. 1993). 
 
Human muscle in cross section stained with Haematoxylin and Eosin. a) Normal muscle. b) Dystrophic 
muscle showing a large variation in fibre size with both atrophic (X) and hypertrophic (Y) fibres, 
increased internal nuclei (*), increased connective (C) and adipose tissue (A) and the presence of 
regenerating and degenerating fibres (arrow pointing to likely degenerating fibre).  
Fig. 2. Healthy and dystrophic human muscle. 
3.3 Muscle imaging – MRI and ultrasound  
Muscle magnetic resonance imaging has long been used as an adjunct to the diagnosis of 
inflammatory myopathies, but its usefulness in other neuromuscular disorders is increasingly 
recognized (Himmrich, Popov et al.). MRI is able to define the pattern of muscle involvement 
more precisely than clinical examination. Some dystrophies are associated with consistent and 
relatively specific patterns of abnormality on T1-weighted MRI scans of the thighs, calves and 
pelvis. For example, muscle MRI of patients with LGMD2I (FKRP) and LGMD2A (calpain-3) 
show marked signal changes in the adductor muscles, posterior thigh muscles and posterior 
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calf muscles, with additional signal changes of medial gastrocnemius and soleus muscles in 
LGMD2A patients, differentiating these disorders from the other forms of LGMD (Fischer, 
Walter et al. 2005). Muscle MRI in combination with detailed clinical information and 
biochemical analysis is now being used increasingly to guide genetic investigations (Mercuri, 
Pichiecchio et al. 2002; Mercuri, Jungbluth et al. 2005). 
Relatively distinct patterns of muscle involvement have also been described for the 
dystrophinopathies (Lamminen 1990; Lamminen, Tanttu et al. 1990), the 
sarcoglycanopathies (,  and ) (Eymard, Romero et al. 1997; Lodi, Muntoni et al. 1997), 
dysferlinopathy (Meola, Sansone et al. 1996; Cupler, Bohlega et al. 1998; Suzuki, Aoki et al. 
2004; Paradas, Llauger et al. 2010), Bethlem myopathy (Mercuri, Cini et al. 2002; Mercuri, 
Cini et al. 2003; Mercuri, Lampe et al. 2005), and for mutations in ANO5 (Hicks, Sarkozy et 
al. 2011), LMNA, EMD (Mercuri, Counsell et al. 2002), and TTN (Udd, Vihola et al. 2005). 
Muscle MRI has been used to direct investigations in older patients with CMD, since 
distinctive patterns of muscle involvement are described for Ullrich CMD (Mercuri, Cini et 
al. 2002; Mercuri, Cini et al. 2003; Mercuri, Lampe et al. 2005) and SEPN1-related 
myopathies (Flanigan, Kerr et al. 2000; Mercuri, Talim et al. 2002; Mercuri, Clements et al. 
2010). The need for a general anaesthetic to perform an MRI scan on patients less than age 5 
years makes it a less attractive investigation for young patients.  
Muscle MRI can also assist in choosing an appropriate muscle to biopsy, so that muscles that 
are affected by the disease process but not completely atrophied are targeted (Norwood, de 
Visser et al. 2007). 
3.4 Protein analysis 
While the specific type of MD can rarely be defined from routine histological stains, 
immunohistochemistry (IHC) and Western blot (WB) analysis of the expression of several MD 
proteins can be extremely useful to identify the likely genetic cause (Vogel and Zamecnik 2005; 
Bushby, Norwood et al. 2007). It is important that these studies are performed in a laboratory 
with expertise in these techniques (Norwood, de Visser et al. 2007). IHC is used to identify 
whether the protein is present or absent and whether it is normally localised. WB is generally 
more sensitive to reductions in protein expression but is technically more challenging. IHC has 
well-established roles in the diagnosis of the CMDs (Peat, Smith et al. 2008), the 
dystrophinopathies (Bonilla, Samitt et al. 1988; Hoffman, Fischbeck et al. 1988; Jones, Kim et al. 
1998) and the sarcoglycanopathies (Vainzof, Passos-Bueno et al. 1996; Bonnemann, Wong et al. 
2002) in particular. However, IHC is not helpful in all forms of MD. For example, in some 
dominant LGMDs such as LGMD1B, lamin A/C staining usually appears normal by IHC (Lo, 
Cooper et al. 2008). Mild to moderate ‘secondary’ staining abnormalities can arise in 
association with a primary abnormality in another protein or due to the disease process itself. 
Therefore the results of a single stain should always be considered in the context of other IHC 
results, the clinical situation and ideally protein quantification on Western blot (Ohlendieck, 
Matsumura et al. 1993; Mizuno, Yoshida et al. 1994; Vainzof, Passos-Bueno et al. 1996; Jones, 
Kim et al. 1998 (Lo, Cooper et al. 2008). For example, absence of dystrophin in DMD often 
results in partial loss of staining of other components of the dystrophin-associated protein 
complex (e.g. the sarcoglycans) and merosin. Reduced or abnormal localisation of dysferlin by 
IHC occurs in ~45% of all dystrophic muscle biopsies (Lo, Cooper et al. 2008), and it is only the 
absence of dysferlin by IHC and WB that indicates a primary dysferlinopathy. 
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Obtaining a muscle biopsy from a patient is an invasive procedure and biopsies are precious 
resources for both diagnosis and research. The single section WB technique (Cooper, Lo et al. 
2003) has been an important advance on traditional methods by significantly reducing the 
amount of muscle biopsy used for each blot, from 20 - 100 mg down to one 8 m cryosection. 
WB analysis has been found to be more  effective for diagnosis than IHC for several forms of 
LGMD, such as LGMD2B (dysferlin) (Vainzof, Anderson et al. 2001; Nguyen, Bassez et al. 
2005; Lo, Cooper et al. 2008), LGMD1C (caveolin-3) (Minetti, Sotgia et al. 1998; Carbone, Bruno 
et al. 2000; Herrmann, Straub et al. 2000; Lo, Cooper et al. 2008) , Becker MD (dystrophin) 
(Voit, Stuettgen et al. 1991) and arguably the alpha-dystroglycanopathies (Peat, Smith et al. 
2008). However the sensitivity and specificity of WB is relatively poor for LGMD2A (calpain-3) 
(Fanin, Fulizio et al. 2004; Saenz, Leturcq et al. 2005; Groen, Charlton et al. 2007; Lo, Cooper et 
al. 2008) and the laminopathies (Menezes et al. 2011). 
3.5 Genetic analysis 
A provisional diagnosis can often be made by considering the clinical information, muscle 
pathology and protein studies, which can then be confirmed by direct gene sequencing 
(Bushby, Norwood et al. 2007; Norwood, de Visser et al. 2007). Even with recent advances, it 
is often difficult to correctly predict the correct LGMD sub-type and several genes may need 
to be tested before a definitive diagnosis is made. If genetic testing identifies mutations 
previously published or listed in on-line databases, a firm diagnosis can be made. However, 
if previously unreported genetic changes are found, then further functional protein studies 
may be useful to differentiate pathogenic mutations from rare harmless sequence variants.  
Even in the best diagnostic centres, establishing a genetic cause for MD is only possible in 
around 90% of patients. Likely reasons are that the full phenotypic spectrum of many 
known genes is still being clarified and many MD genes likely remain unidentified. Whole 
exome or whole genome sequencing and other techniques that capitalise on recent advances 
in gene sequencing are likely to provide new opportunities to diagnose patients with MD. 
These approaches also have the capacity to identify new MD disease genes, which may 
account for many of the currently undiagnosed patients worldwide. 
4. Diagnosis in specific forms of muscular dystrophy 
4.1 Myotonic dystrophy 
Myotonic dystrophy can usually be suspected from clinical examination and family history 
(see Section 2) and the clinician should have a low threshold for requesting genetic testing 
for DM1 since it is so common. Electromyography (EMG) is useful for showing 
characteristic myotonic discharges although these may not be present in young children 
with DM1 and in the occasional adult patient with DM2. Both DM1 and DM2 are multi-
system disorders and involve predisposition to cataracts, cardiac conduction defects, 
cardiomyopathy, testicular failure and diabetes, as well as myotonia and muscle weakness. 
In myotonic dystrophy, muscle biopsy histopathology lacks specific diagnostic features but 
common features include smallness of a particular fibre type (type 1 atrophy in DM1 and type 
2 atrophy in DM2), prominent internal nuclei and mild dystrophic changes. Genetic testing for 
DM1 is widely available and involves assessment of the size of a triplet repeat (CTG) in the 
DMPK gene (normal 5-34 repeats, asymptomatic/premutation 35-49 repeats, mild DM1 
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phenotype 50-~150, classical DM1 ~100-1000, congenital DM1 > 2000 repeats), (2000; Turner 
and Hilton-Jones 2010). Repeat numbers correlate only approximately with the severity of the 
phenotype and a normal genetic test excludes this condition. There is a tendency for the 
disease severity of DM1 to worsen when inherited by descendents due to further expansion in 
the size of the DMPK gene CTG repeat, a phenomenon called anticipation. 
DM2 should be considered as a diagnosis if there are strong clinical clues for DM1 in an 
adult but genetic testing for DM1 is normal. In DM2, proximal limb weakness is more 
prominent than in DM1, weakness of facial and ankle dorsiflexor muscles may be less 
prominent and a congenital-onset form has not been described (Turner and Hilton-Jones 
2010). Genetic testing for DM2, which is caused by an expansion of a quadruplet repeat 
(CCTG) the ZNF9 gene, is technically more challenging and is less widely performed.  
4.2 Facioscapulohumeral MD (FSHD) 
A diagnosis of FSHD should be suspected when there is prominent (often asymmetric) 
weakness of muscles of the face, scapular stabilisers, upper arms and ankle dorsiflexor 
muscles that begins in late childhood to young adulthood on clinical examination (Sorrel-
Dejerine and Fardeau 1982). With disease progression many other muscle groups become 
involved such as neck extensors, abdominal and pelvic muscles. Although FSHD follows an 
autosomal dominant pattern of inheritance, a negative family history does not exclude the 
condition as reduced penetrance (~10% especially in women) and de novo mutations (~20%) 
are relatively common. If a diagnosis of FSHD is considered possible on the basis of a 
clinical examination, genetic testing is the first investigation of choice since muscle biopsy 
usually shows non-specific dystrophic abnormalities and no protein studies are helpful. 
FSHD has a complex genetic cause that is not yet fully understood, but is associated with 
reduced numbers of large scale D4Z4 repeats in the subtelomeric region of chromosome 4. 
Genetic testing for the 4q deletion is technically challenging and is only 95% sensitive for the 
condition with the possibility of intermediate results, which are often difficult to interpret. 
As a result, testing is best conducted in an experienced laboratory, and family studies and 
the input of a clinical geneticist may assist when results are unclear.  
4.3 Duchenne muscular dystrophy (DMD) 
The diagnosis of DMD can usually be suspected on the basis of family history, age of onset, 
and clinical examination. DMD is an X-linked disorder that usually only affects males. 
Serum CK levels are markedly elevated in all male patients from birth. DMD gene testing 
using multiplex ligation-dependent probe amplification (MLPA) is a useful preliminary test 
that detects exon deletions or duplications and is diagnostic in about 75% of DMD patients 
(and in around 90% of BMD patients). If MLPA is negative, a muscle biopsy is often 
requested for protein studies. Marked dystrophic features are usually present and absence 
of dystrophin protein using IHC and/or WB is also diagnostic for DMD (Figure 3). These 
methods can also be used to detect reduced protein levels or the presence of a truncated 
protein product in patients with the milder form of the condition, Becker MD (BMD). 
Dystrophin sequencing may be required to determine point mutations that cannot be 
detected with MLPA. Around two-thirds of women who have a son with DMD are carriers 
of the mutation and gonadal mosaicism is relatively common in women who test negative 
for the mutation in DNA from blood leukocytes. Identifying the mutation causing DMD in  
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IHC and WB confirm dystrophin-deficiency in a patient with suspected DMD (P1). All patient muscle is 
stained with spectrin (NCL-SPEC1, Leica Microsystems, Wetzlar, Germany) as a control for membrane 
integrity. Three antibodies raised to different epitopes spanning the large dystrophin protein are used 
to help distinguish between total absence of dystrophin (DMD) and reduction or truncation of 
dystrophin (BMD) (NCL-Dys1, 2 & 3, Leica Microsystems, Wetzlar, Germany). Primary loss of 
dystrophin can result in secondary reductions in other members of the dystrophin-protein complex 
(sarcoglycans, dystroglycans) as shown here by a secondary reduction in -sarcoglycan (NCL-SARC, 
Leica Microsystems, Wetzlar, Germany), compared to control muscle. Western blot confirms absence of 
dystrophin protein when probed with the three dystrophin antibodies, strongly suggesting a primary 
abnormality in dystrophin which was confirmed by DMD gene analysis. Coomassie staining of myosin 
is used to show that equal amounts of protein are loaded for both patient and control in the WB. 
Fig. 3. Immunohistochemistry and Western blot analysis of dystrophin and -sarcoglycan in 
the diagnosis of a patient with DMD. 
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each family is extremely useful so that highly accurate genetic testing is available for other 
women in the family who may be at risk of having affected sons. Approximately 10% of 
females with DMD gene mutations will show signs of muscle weakness (manifesting 
carriers) due to skewing of their ratio of X-chromosome inactivation, but most only become 
symptomatic during adulthood with mild muscle weakness and/or cardiomyopathy. 
4.4 LGMD2B (dysferlinopathy) 
A diagnosis of LGMD2B, due to autosomal recessive mutations in the DYSF gene, should be 
considered in patients with muscle weakness that begins in the late teenage years or early 
adulthood. It is common for DYSF patients to present with early involvement of calf 
muscles (also called Miyoshi myopathy) and difficulty standing on tip-toes. However, some 
DYSF patients present with a classical LGMD pattern of weakness involving the hip and 
shoulder girdles. Early calf wasting markedly raised serum CK levels (often 5000 – 20 000 
U/ml) are distinguishing features of a primary dysferlinopathy, in contrast to many other 
forms of MD with calf hypertrophy. DYSF patient biopsy samples often display a prominent 
inflammatory cell infiltrate, sometimes leading to misdiagnosis of polymyositis. A range of 
abnormal dysferlin staining patterns are seen in many types of MD as non-specific 
secondary abnormalities (see Figure 4b), but complete absence of staining by IHC and WB 
(Figure 4a) is specific for LGMD2B.  
 
a) IHC of LGMD2B patient muscle shows a severe reduction in dysferlin (NCL-Hamlet, Leica 
Microsystems) staining at the muscle membrane compared to control muscle, and a corresponding loss 
of dysferlin by WB (P2). Genetic analysis of this patient confirmed mutations in the DYSF gene. 
b) Secondary reductions and abnormal dysferlin protein localisation by IHC occur commonly as 
secondary abnormalities in many dystrophies but absence on WB is specific to dysferlinopathies.  
Fig. 4. Immunohistochemistry and Western blot analysis of dysferlin in the diagnosis of 
LGMD2B.  
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4.5 LGMD2I 
Patients with LGMD2I, due to autosomal recessive mutations in FKRP, usually present with 
a classical LGMD pattern of weakness, often with greater involvement of the lower limbs, 
and calf hypertrophy. Some patients also have macroglossia (an enlarged tongue) and ankle 
contractures. -dystroglycan staining by IHC is usually reduced in LGMD2I patients (see 
Figure 5), although the reduction may be subtle and is rarely absent. WB can be used to look 
for reduction of glycosylated -dystroglycan, which usually appears as a smeared band at 
~156 kDa due to variable glycosylation of the core protein which results in a range of final 
molecular weights (Figure 5). Almost all LGMD2I patients have at least one copy of the 
c.826C>A (L276I) mutation, a founder mutation that is particularly common in Northern 
European populations (Walter, Petersen et al. 2004). Severe reductions in -dystroglycan by 
IHC and WB can also be associated with other mutations in FKRP, or with mutations in the 
other ‘alpha-dystroglycanopathy’ genes encoding glycosylation enzymes that result in 
CMD, WWS or MEB phenotypes (see Table 1).  
 
-dystroglycan levels are reduced by IHC and WB (using both VIA41 (Millipore, CA, USA) and IIH6 
(kind gift from Dr Kevin Campbell) antibodies that recognize glycosylated -dystroglycan, in a number 
of glycosyltransferase disorders. Specific genetic testing is required to determine the particular genetic 
cause. In this case the patient was found to have recessive mutations in the FKRP gene, causing LGMD2I.  
Fig. 5. Immunohistochemistry and Western blot analysis of -dystroglycan in a patient with 
LGMD2I. 
4.6 Emery-Dreifuss muscular dystrophy (EDMD) 
EDMD should be suspected in patients who develop early joint contractures, particularly of 
the elbows, neck extensors and tendo-Achilles. Patients present with progressive muscle 
weakness and wasting particularly of the upper arm and ankle dorsiflexor muscles, and 
often develop cardiac abnormalities (heart block, arrhythmias or cardiomyopathy). 
Mutations in three genes are associated with this phenotype, LMNA (which follows 
autosomal dominant inheritance), EMD and FHL1 (both X-linked genes), but further genetic 
causes are likely. IHC for emerin in skeletal muscle shows from the nuclear envelope in X-
linked EDMD due to EMD mutations and is specific for this condition (see Figure 6). Emerin 
is also completely absent by WB in these patients (Figure 6). Finding mutations on EMD 
gene sequencing confirms the diagnosis and allows for carrier testing of at-risk females. 
There are no robust protein-based screening tests for LMNA mutations and direct 
sequencing is required to exclude the diagnosis. Clinicians should have a low threshold for 
testing both the EMD and LMNA genes if a diagnosis of EDMD is possible, due to the risk of 
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developing potentially lethal cardic arrhythmias. Early diagnosis allows for introduction of 
close cardiac surveillance by electrocardiogram (ECG), Holter ambulatory ECG monitoring, 
echocardiography and the early use of implantable cardiac defibrillators to reduce 
morbidity and mortality. 
 
Examples of Emerin immunostaining is absent from the nuclear envelope in muscle from a patient with 
X-linked EDMD (nuclei are stained by DAPI (4',6-diamidino-2-phenylindole, dihydrochloride), 
Invitrogen, CA, USA). WB analysis shows absent staining for emerin (P4),  and a genetic mutation 
(c.651_655dupGGGCC) was later identified. Immunoblot for caveolin-3 and coomassie staining of actin 
are used to show equal protein loading.  
Fig. 6. Immunohistochemistry and Western blot analysis of emerin in the diagnosis of EDMD. 
4.7 Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy 
Patients with UCMD usually present with generalised muscle weakness, wasting, hypotonia 
and marked distal laxity from birth (Nonaka, Une et al. 1981; De Paillette, Aicardi et al. 1989; 
Mercuri, Yuva et al. 2002). Clinically, patients often have a distinctive sandpaper-like skin 
rash, congenital hip dislocation, scoliosis, a high arched palate and prominent heels. IHC is a 
useful diagnostic test, and staining of muscle sections with collagen VI in combination with 
a muscle membrane marker, e.g. perlecan or collagen IV, can highlight a characteristic loss 
of collagen VI at the muscle membranes even though collagen VI staining may be retained 
in connective tissue between fibres (Figure 7). Reduced secretion of collagen VI by cultured  
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In UCMD and Bethlem myopathy, collagen VI is reduced or lost at the plasma membrane of muscle 
fibres but may be present in interstitial connective tissue. After carefully optimising conditions to 
achieve equal intensity of collagen VI (70-XR95, Fitzgerald Industries International Inc, MA, USA) and 
perlecan (A7L6, MAB1948, Miilipore, CA, USA) staining in control muscle, an overlay image can 
identify a reduction in collagen VI, relative to perlecan, at the muscle sarcolemmal membrane. In this 
example, an overlay image from control muscle appears mostly yellow/orange, with broadly equal 
intensities of perlecan (green) and collagen VI (red) staining. In contrast, an overlay image from a 
UCMD patient, reveals a dominance of perlecan (green labelling), indicating a relative deficiency of 
collagen VI (red label) at the muscle membrane. These results are consistent with a primary 
collagenopathy, and a dominant mutation was identified in the COL6A2 gene. 
Fig. 7. Immunohistochemistry analysis of collagen VI in the diagnosis of UCMD. 
patient fibroblasts strongly supports a diagnosis of UCMD or Bethlem myopathy but genetic 
testing of the three genes that code for collagen VI chains (see Table 1) is required to confirm 
the diagnosis. Collagen VI gene mutations that do not result in severe protein abnormalities 
usually present in childhood with a less severe phenotype called Bethlem myopathy. 
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Progressive joint contractures are major sources of morbidity in both UCMD and Bethlem 
myopathy and close monitoring for scoliosis and respiratory insufficiency is important, 
particularly in UCMD. 
5. Frequency of diagnosis of less common types of MD 
The frequency of some forms of MD varies widely in different parts of the world, which can 
influence the most appropriate diagnostic approach to follow in different countries.  
LGMD2A accounted for 50% of all LGMD patients in a Turkish study (Dincer, Leturcq et al. 
1997), around 25% of patients in Italy (Guglieri, Magri et al. 2008; Fanin, Nascimbeni et al. 
2009) and the United Kingdom (UK) (Norwood, Harling et al. 2009) but only 5-8% in 
American (Moore, Shilling et al. 2006), Brazilian (Vainzof, Passos-Bueno et al. 1999) and 
Australian (Lo, Cooper et al. 2008) studies. Although different diagnostic techniques may 
account for some of the variability, this finding points to major regional differences in the 
frequency of CAPN3 gene mutations in different populations. Similarly LGMD2I seems 
particularly prevalent in Scandinavia (Sveen, Schwartz et al. 2006) and the UK (Norwood, 
Harling et al. 2009) compared with other populations (see Table 3). High rates of known 
genetic forms of LGMD likely contribute to a high overall rate of LGMD diagnosis in Turkey 
(Dincer, Leturcq et al. 1997), the UK (Norwood, Harling et al. 2009) and Denmark (Sveen, 
Schwartz et al. 2006). The rates identified for many forms of LGMD are similar in Australia 
(Lo, Cooper et al. 2008) to the USA (Moore, Shilling et al. 2006) and it is interesting that both 
populations are comprised of a mixture of ethnicities. 
 
 LGMD Total 
Diagnosis 1A 1B 1C 2A 2B 2C,D,E,F 2G 2I 
Denmark 1 NA NA NA 12% 2% 22% NA 37% 73% 
Turkey 2 NA NA NA 50% 5% 20% NA NA 75% 
Italy 3 0% 0% 1.3% 28% 19% 18% 0% 6% 73% 
Northern England 4  9%  26% 6% 12%  19% 72% 
USA 5 0.6% 7% 0% 9% 3% 19% NA 7% 46% 
Italy 6 NA 1% 1.5% 19% 8% 11% NA 3% 43% 
Brazil 7 NA NA NA 5% 3% 17% NA NA 24% 
Australia 8 NA 1% 2.6% 8% 5% 2.6% NA 2.6% 23% 
Brazil 9 NA NA NA 32% 22% 32% 3% 11% N/A 
LGMD = limb-girdle muscular dystrophy. NA = not assessed, N/A = retrospective review, no total 
diagnosis stated. References: 1(Sveen, Schwartz et al. 2006), 2(Dincer, Leturcq et al. 1997), 3(Guglieri, 
Magri et al. 2008), 4(Norwood, Harling et al. 2009), 5(Moore, Shilling et al. 2006), 6(Fanin, Nascimbeni et 
al. 2009), 7(Vainzof, Passos-Bueno et al. 1999), 8(Lo, Cooper et al. 2008) and 9(Zatz, de Paula et al. 2003). 
Table 3. Diagnoses in LGMD cohort studies. 
As for LGMD, the proportions of some forms of CMD have varied widely between studies 
in different countries. A Brazilian study diagnosed merosin-deficiency in around 40% of 
CMD patients (Ferreira, Marie et al. 2005), while this diagnosis accounted for only 8% of 
CMD patients in an Australian study (Peat, Smith et al. 2008). Differences in CMD 
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ascertainment criteria may be partly responsible but it is likely there are true differences in 
disease incidence in different populations. Similarly, different rates of collagen VI diagnoses 
have been observed, ranging from 8% in Australia (Peat, Smith et al. 2008) to 1.7% in Brazil 
(Ferreira, Marie et al. 2005).  
6. Future directions 
In the past, genetic testing for MD has involved the sequencing of individual genes that 
were considered likely causes based on clinical presentation and screening tests. The large 
number of possible genetic causes with overlapping phenotypes has made it difficult to 
predict the correct genetic cause in many MD patients and consequently, finding the 
causative mutation in many families has often been a prolonged, expensive exercise. Recent 
advances in gene sequencing are likely to have a major impact on the diagnosis of MD in the 
near future. It is now possible to sequence multiple muscle disease genes and even the 
whole genome relatively cheaply in a single experiment (Metzker 2010). Next generation 
sequencing technologies will also facilitate the discovery of new MD genes, leading to 
increased rates of patient diagnosis. As thesetechnologies become more routinely used and 
costs reduce, the approach to diagnosing forms of MD such as, LGMD, that have many 
possible genetic causes is likely to move from the sequencing of individual candidate genes 
towards a multi-gene or genome-wide sequencing approach. Some diagnostic centres 
worldwide are already implementing this technology for the diagnosis of MDs. These 
methods bring new challenges, such as distinguishing genetic sequence variants that are the 
primary cause of the disease from variants that modify a phenotype or are harmless 
polymorphisms. It is likely that there will always be a need for centres with expertise in 
clinical phenotyping and protein studies to clarify the diagnosis when genetic analysis alone 
cannot confirm whether a sequence variant in a gene is truly disease-causing or not. 
7. Glossary 
BMD Becker muscular dystrophy 
CK Creatine kinase 
CMD Congenital muscular dystrophy 
DMD Duchenne muscular dystrophy 
DM Myotonic dystrophy (DM1 Type 1, DM2 Type 2) 
ECG Electrocardiogram 
EDMD Emery Dreifuss muscular dystrophy 
FCMD  Fukuyama congenital muscular dystrophy  
FSHD  Facioscapulohumeral muscular dystrophy 
IHC Immunohistochemistry 
LGMD Limb girdle muscular dystrophy (Type 1 dominant, Type 2 recessive) 
MD Muscular dystrophy 
MEB  Muscle-eye-brain disease 
MLPA Multiplex Ligation-dependent Probe Amplification 
MRI Magnetic resonance imaging 
UCMD  Ullrich congenital muscular dystrophy 
UK United Kingdom 
WB Western blot 
WWS  Walker-Warburg Syndrome 
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